Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 23, 2026
Why Is Albertsons Companies (ACI) Stock Down -21.64% Today?

Why Is Albertsons Companies (ACI) Stock Down -21.64% Today?

Key Takeaways

  • Albertsons Companies shares plunged 21.64% on Thursday, trading near $11.44 after closing at $14.60 the prior session.
  • The primary catalyst was a disappointing fiscal Q1 2026 earnings report featuring a 22% miss on adjusted EPS and a sharp cut to full-year guidance.
  • Identical sales fell 0.8%, gross margins contracted, and management cited softening industry trends and a more cautious consumer — particularly among lower-income households.
  • The company announced ACI Edge, a sweeping restructuring consolidating 11 divisions into four regions, alongside the pending retirement of CFO Sharon McCollam.
  • Broader grocery sector sentiment has been under pressure, with peer performance and competitive dynamics from Walmart and Aldi adding to investor unease.
  • Traders are now watching for further analyst downgrades, execution on the restructuring plan, and whether consumer headwinds persist through the remainder of fiscal 2026.

Opening Summary

ACI, the parent company of Albertsons Companies, Inc. — one of the largest food and drug retailers in the United States, operating over 2,200 stores under banners including Safeway, Jewel-Osco, Vons, and Shaw's — suffered a punishing selloff on Thursday. Shares of ACI dropped 21.64% to trade at approximately $11.44, down from the prior session's close of $14.60. The decline followed the release of the company's fiscal first-quarter 2026 results before the opening bell, which fell well short of Wall Street expectations and triggered a wave of selling that pushed the stock to near its 52-week low.

Earnings Miss and Deteriorating Margins

The immediate trigger for the selloff was Albertsons' fiscal Q1 2026 earnings report for the 16-week period ended June 20. The company posted adjusted earnings of $0.42 per share, missing the analyst consensus of $0.54 by a wide margin of roughly 22%. Net income tumbled to $84.7 million, or $0.17 per share, compared with $236.4 million, or $0.41 per share, in the same quarter a year ago.

While revenue of $24.94 billion narrowly exceeded Street estimates of $24.83 billion, the top-line beat was overshadowed by deteriorating profitability metrics. Gross margin contracted to 26.6% from 27.1% a year earlier, pressured by higher delivery and handling costs tied to digital sales growth and rising fuel expenses. Selling and administrative expenses also climbed as a percentage of revenue. Identical sales — a critical metric for retail — declined 0.8%, reflecting softer grocery unit trends and continued pressure on lower-income shoppers.

Full-Year Guidance Slashed

Compounding the earnings miss, Albertsons delivered a sobering revision to its fiscal 2026 outlook. Management now expects adjusted EPS in a range of $1.75 to $1.85, a dramatic markdown from the prior range of $2.22 to $2.32 and well below the analyst consensus of $2.27. The company also lowered its identical sales forecast to a decline of 0.5% to 1.5%, reversing earlier guidance that called for flat to 1% growth. Adjusted EBITDA guidance was reduced to $3.550 billion–$3.625 billion from $3.850 billion–$3.925 billion.

CEO Susan Morris acknowledged that the results "did not meet our expectations" and pointed to "softer industry unit trends and a more cautious consumer" as headwinds. The company's commentary underscored that core grocery faces increasing competitive intensity, with lower-income customers trading down to private-label products and value-oriented competitors including Walmart, Amazon, and Aldi.

Restructuring and CFO Departure

In conjunction with the earnings release, Albertsons unveiled ACI Edge, an ambitious operating model restructuring. The plan consolidates the company's 11 operating divisions into four regions — California, West, South, and East — and centralizes center-store merchandising under a single enterprise team. Management expects the realignment to generate approximately $200 million in annual run-rate benefits, with the majority of savings realized in fiscal 2027. However, the restructuring also signals acknowledgment that the existing operating structure was not delivering adequate performance.

Adding to the uncertainty, the company announced that President and CFO Sharon McCollam — who joined Albertsons in 2021 and was instrumental in shaping its financial strategy — plans to retire later this year. A search for her successor is underway. While McCollam will remain in an advisory capacity through the end of the fiscal year, the departure of a key financial leader during a period of operational overhaul added another layer of concern for investors.

Market Context and Trading Activity

Thursday's plunge in ACI shares was accompanied by exceptionally heavy trading volume, reflecting intense institutional repositioning following the earnings release. The stock pierced through multiple technical support levels and traded near its 52-week low of $11.68, a level that now serves as the last line of defense for bulls. The move far exceeded any broader market or sector decline, indicating that the selloff was overwhelmingly company-specific rather than macro-driven.

The grocery retail sector has been under pressure broadly as inflationary fatigue and shifting consumer behavior reshape the competitive landscape. Rival KR (Kroger) has faced similar headwinds, adding to the cautious tone across the industry. The market's reaction to Albertsons' results suggests that investors are pricing in a more protracted recovery timeline, particularly given management's own acknowledgment that improvement will be gradual.

Trending AI Robots

In volatile market environments like the one affecting ACI today, traders often turn to AI-powered tools to navigate uncertainty and identify actionable signals. Tickeron offers hundreds of AI trading bots covering thousands of tickers across equities, ETFs, and forex, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by trading strategy, timeframe, performance metrics, and the symbols they trade, allowing users to find approaches aligned with their own objectives. For those seeking data-driven insights during periods of heightened volatility, exploring the Trending AI Robots page can provide a useful starting point.

What Comes Next for ACI

The road ahead for ACI hinges on several factors. First, the successful execution of the ACI Edge restructuring will be closely monitored — investors will look for tangible margin improvements and signs that the new regional model is delivering faster decision-making and better in-stock performance. Second, the search for a new CFO will attract significant attention, as the incoming executive will inherit a complex turnaround story.

On the macro front, consumer spending trends among lower- and middle-income households remain a key variable. Management signaled that it expects only gradual improvement in industry unit trends, meaning the near-term earnings trajectory may remain challenged. The company's pharmacy business, while pressured by Inflation Reduction Act headwinds, continues to grow scripts and immunizations and could serve as a stabilizing force. Digital sales growth of 13% and the first quarter of e-commerce profitability also offer bright spots. Analysts may revise ratings and price targets in the coming days, which could further influence trading sentiment. Risks include persistent grocery price competition, elevated operating costs, and the potential for additional guidance revisions if consumer headwinds deepen.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACI

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ACI's RSI Oscillator recovers from oversold territory

The RSI Oscillator for ACI moved out of oversold territory on July 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on ACI as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ACI just turned positive on August 07, 2026. Looking at past instances where ACI's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACI advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ACI entered a downward trend on July 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.686) is normal, around the industry mean (3.277). P/E Ratio (76.562) is within average values for comparable stocks, (55.906). Projected Growth (PEG Ratio) (1.310) is also within normal values, averaging (1.258). ACI's Dividend Yield (0.052) is considerably higher than the industry average of (0.023). P/S Ratio (0.078) is also within normal values, averaging (8.969).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

Notable companies

The most notable companies in this group are Kroger Co (The) (NYSE:KR).

Industry description

The food retail industry includes companies that sell food, beverage and household products. Items sold include grocery, gourmet food, fresh produce, and frozen food. Kroger Co., George Weston Ltd., Grocery Outlet Holding Corp., and Sprouts Farmers Markets, Inc. are examples of major food retailers. While e-commerce companies like Amazon have increasingly been ramping-up offerings in the food retail space, several traditional players have also been expanding their online presence to stand their ground against rising competition.

Market Cap

The average market capitalization across the Food Retail Industry is 3.98B. The market cap for tickers in the group ranges from 30.44K to 51.3B. LBLCF holds the highest valuation in this group at 51.3B. The lowest valued company is QKLS at 30.44K.

High and low price notable news

The average weekly price growth across all stocks in the Food Retail Industry was 2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -14%. HCWC experienced the highest price growth at 35%, while NGVC experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Food Retail Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was -16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 42
P/E Growth Rating: 45
Price Growth Rating: 63
SMR Rating: 76
Profit Risk Rating: 79
Seasonality Score: -59 (-100 ... +100)
View a ticker or compare two or three
ACI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which engages in production and distribution of thermal coal

Industry FoodRetail

Profile
Details
Industry
N/A
Address
250 Parkcenter Boulevard
Phone
+1 208 395-6200
Employees
290000
Web
https://www.albertsonscompanies.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.